A financially driven corporate life science venture fund’s purpose is to foster innovation, drive significant patient benefit and generate superior returns by creating and investing in innovative life science companies at various stages of their development, independent form their parent company’s strategy. The firm has offices in USA and Europe, where the firm also focuses its investment activities. The firm has an evergreen structure and currently holds $800 million in assets under management. The firm typically makes equity investments in early venture rounds, investing up to $25 million over multiple financing rounds with 6-8 investments in any given year.
The firm invests in therapeutics with a focus on pre-IND assets and Series A investment rounds. The firm is interested in all classes and indications of innovative therapeutics with paradigm shifting potential.
The firm invests exclusively in privately held companies and aims to be a lead or co-lead with a director position.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply